Recent Securities Litigations

Indivior PLC (US TRADING VENUE: INVVY)

Company Name:Indivior PLC
Stock Symbol:US TRADING VENUE: INVVY
Class Period Start:03/10/2015
Class Period End (inclusive):04/09/2019

According to the Complaint, Indivior together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The Company’s product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia.

The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Indivior and its executives engaged in an illicit nationwide scheme to increase prescriptions of Suboxone Film; (2) Indivior illegally obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs; (3) as a result of the aforementioned misconduct, Indivior would face felony charges; and (4) due to the foregoing, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On July 30, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on September 30.